Literature DB >> 31376458

Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions.

Manale Harfouche1, Hiam Chemaitelly1, Laith J Abu-Raddad2.   

Abstract

OBJECTIVE: To assess herpes simplex virus type 1 (HSV-1) epidemiology in Africa.
METHODS: This systematic review was conducted per the Cochrane Collaboration guidelines. Findings were reported following the PRISMA guidelines. Research questions were addressed using random-effects meta-analyses and meta-regressions.
RESULTS: Forty-three overall (and 69 stratified) HSV-1 seroprevalence measures, and 18 and eight proportions of HSV-1 viral detection in genital ulcer disease (GUD) and in genital herpes, respectively, were extracted from 37 reports. Pooled mean seroprevalence was 67.1% (95% confidence interval (CI): 54.7-78.5%) in children, and 96.2% (95% CI: 95.0-97.3%) in adults. Across age groups, pooled mean was 44.4% (95% CI: 29.9-59.3%) in ≤5 years-old, 85.6% (95% CI: 81.0-89.6%) in 6-15 years-old, 93.3% (95% CI: 89.2-96.6%) in 16-25 years-old, and 93.8% (95% CI: 84.6-99.4%) in >25 years-old. Age explained 78.8% of seroprevalence variation. Pooled mean proportion of HSV-1 detection was 0.4% (95% CI: 0.0-1.5%) in GUD, and 1.2% (95% CI: 0.0-4.0%) in genital herpes.
CONCLUSIONS: HSV-1 is universally prevalent in Africa, at higher levels than other regions, with no evidence for declines in seroprevalence in recent decades. Nearly every person acquires the infection in childhood through oral-to-oral transmission, before sexual debut. Sexual oral-to-genital and genital-to-genital transmission appear very limited.
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Genital herpes; Genital ulcer disease; Region; Seroprevalence; Synthesis

Year:  2019        PMID: 31376458     DOI: 10.1016/j.jinf.2019.07.012

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  7 in total

1.  Sophoridine Suppresses Herpes Simplex Virus Type 1 Infection by Blocking the Activation of Cellular PI3K/Akt and p38 MAPK Pathways.

Authors:  Qiong Tang; Fei Luan; An Yuan; Jiayi Sun; Zhili Rao; Baojun Wang; Yao Liu; Nan Zeng
Journal:  Front Microbiol       Date:  2022-06-10       Impact factor: 6.064

2.  Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions.

Authors:  Manale Harfouche; Farah M Abu-Hijleh; Charlotte James; Katharine J Looker; Laith J Abu-Raddad
Journal:  EClinicalMedicine       Date:  2021-05-07

3.  Epidemiology of herpes simplex virus type 2 in Asia: A systematic review, meta-analysis, and meta-regression.

Authors:  Sawsan AlMukdad; Manale Harfouche; Anja Wettstein; Laith J Abu-Raddad
Journal:  Lancet Reg Health West Pac       Date:  2021-06-09

4.  Seroprevalence of Human Herpesvirus Infections in Newly Diagnosed HIV-Infected Key Populations in Dar es Salaam, Tanzania.

Authors:  Doreen Kamori; Agricola Joachim; Mucho Mizinduko; Godfrey Barabona; Macdonald Mahiti; Upendo Kibwana; Mtebe Majigo; Salim Masoud; Ambele M Mwandigha; Takamasa Ueno; Elia Mmbaga; Eligius Lyamuya
Journal:  Int J Microbiol       Date:  2021-08-25

5.  Herpes simplex virus type 1 in Europe: systematic review, meta-analyses and meta-regressions.

Authors:  Wajiha Yousuf; Hania Ibrahim; Manale Harfouche; Farah Abu Hijleh; Laith Abu-Raddad
Journal:  BMJ Glob Health       Date:  2020-07

6.  Herpes simplex virus type 1 infection leads to neurodevelopmental disorder-associated neuropathological changes.

Authors:  Haowen Qiao; Moujian Guo; Jia Shang; Wen Zhao; Zhenyan Wang; Nian Liu; Bin Li; Ying Zhou; Ying Wu; Pu Chen
Journal:  PLoS Pathog       Date:  2020-10-22       Impact factor: 6.823

7.  Genital HSV-1 DNA detection is associated with a low inflammatory profile in HIV-uninfected South African women.

Authors:  Andile Mtshali; Sinaye Ngcapu; Farzana Osman; Nigel Garrett; Ravesh Singh; Anne Rompalo; Adrian Mindel; Lenine J P Liebenberg
Journal:  Sex Transm Infect       Date:  2020-08-26       Impact factor: 3.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.